{"disease":{"id":"poliomyelitis","name":"poliomyelitis"},"drugs":{"marketed":[{"drug_id":"dtacp-ipv-combined-vaccine-tetraxim","indication_name":"Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in children 6 weeks through 6 years of age","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DTacP-IPV combined vaccine (TETRAXIM™)","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"Diphtheria toxin, tetanus toxin, Bordetella pertussis antigens (PT, FHA, PRN), poliovirus types 1, 2, and 3","drug_class":"Combination inactivated vaccine","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""},{"drug_id":"pediarix","indication_name":"Protection against diphtheria, tetanus, pertussis (whole-cell), hepatitis B, poliomyelitis (inactivated), and Haemophilus influenzae type b (Hib) disease in infants and children from 6 weeks through 6 years of age, when used in a 3-dose series.","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pediarix","generic_name":"pediarix","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Immune system","drug_class":"vaccine","quality_score":37,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04220515","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":49731,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT05432141","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":3200,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT02967783","title":"A Campaign-based ID fIPV Administration Trial","phase":"NA","overall_status":"COMPLETED","enrollment_count":2721,"lead_sponsor_name":"Medical Research Council Unit, The Gambia","has_results":false},{"nct_id":"NCT00325156","title":"Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infants","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2590,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06137664","title":"Study of Trivalent and Bivalent (Types 1 & 2) Novel Oral Poliomyelitis Vaccines","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":2400,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT05644184","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2232,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT05431933","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2001,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT03202719","title":"Duration of IPV Priming and Antibody Decay","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1645,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT05386810","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1572,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05654467","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":1532,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT05850364","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1442,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT05457946","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":1438,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT00463437","title":"Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1437,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03169725","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":1417,"lead_sponsor_name":"LG Chem","has_results":false},{"nct_id":"NCT04386707","title":"Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1300,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03722004","title":"Monovalent Oral Poliovirus Vaccine Type 1 Intestinal and Humoral Immunity Study","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1256,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT05460377","title":"Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1224,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT04224519","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Institute of Medical Biology, Chinese Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03526978","title":"An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT07297186","title":"Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1200,"lead_sponsor_name":"Beijing Minhai Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT01021293","title":"Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1101,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05163561","title":"Evaluation of Safety and Immunogenicity of Inactivated Adjuvanted Polio Vaccine in Comparison With Licensed Inactivated Poliovirus Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1072,"lead_sponsor_name":"Serum Institute of India Pvt. Ltd.","has_results":false},{"nct_id":"NCT03554798","title":"A Study to Evaluate the Safety and Immunogenicity of Novel Oral Polio Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1025,"lead_sponsor_name":"Fidec Corporation","has_results":true},{"nct_id":"NCT03032419","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given at 6, 10, 14 Weeks and 9 Months","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1002,"lead_sponsor_name":"Statens Serum Institut","has_results":false},{"nct_id":"NCT01086423","title":"Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":985,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04063150","title":"Immunogenicity of Intramuscular and Intradermal IPV","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":958,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT01323647","title":"Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":957,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00432042","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":955,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05033561","title":"Study to Evaluate Safety and Immunogenicity of nOPV2 at Different Intervals in Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":905,"lead_sponsor_name":"Fidec Corporation","has_results":true},{"nct_id":"NCT06442449","title":"Booster Dose of sIPV Co-administered With MMR and HepA-I.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":889,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT03025750","title":"Safety and Immunogenicity of Adjuvanted Reduced Dose Inactivated Polio Vaccine in 2, 4, 6 Months of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"Statens Serum Institut","has_results":false},{"nct_id":"NCT04579510","title":"Immunogenicity nOPV2 With and Without bOPV","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":795,"lead_sponsor_name":"Centers for Disease Control and Prevention","has_results":false},{"nct_id":"NCT04614597","title":"A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China","phase":"","overall_status":"COMPLETED","enrollment_count":774,"lead_sponsor_name":"Centers for Disease Control and Prevention, China","has_results":false},{"nct_id":"NCT03239496","title":"A Study to Evaluate Immunogenicity of Intramuscular Full-Dose and Intradermal Fractional Dose of IPV","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":773,"lead_sponsor_name":"Fidec Corporation","has_results":true},{"nct_id":"NCT07010822","title":"A Study to Evaluate the Mucosal Intestinal Immunity to Poliovirus Type-2 of nOPV2 at Birth Dose in Healthy IPV Vaccinated Infants","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":740,"lead_sponsor_name":"Fidec Corporation","has_results":false},{"nct_id":"NCT01248884","title":"Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":721,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00325143","title":"Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":702,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06895486","title":"Study of Co-administered (Types 1 & 2) Novel Oral Poliomyelitis Vaccines Evaluation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":675,"lead_sponsor_name":"PATH","has_results":false},{"nct_id":"NCT03671616","title":"Immunogenicity and Safety of Adjuvanted Reduced Dose Inactivated Polio Vaccine Given as a Booster at Age 15-18 Months","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":666,"lead_sponsor_name":"Statens Serum Institut","has_results":false},{"nct_id":"NCT01453998","title":"Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":657,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01568060","title":"Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02422264","title":"Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02096263","title":"Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03597919","title":"A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":560,"lead_sponsor_name":"Centers for Disease Control and Prevention, China","has_results":false},{"nct_id":"NCT02853929","title":"Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-delivery","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":551,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03723837","title":"Persistence of IPV Immunity","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":502,"lead_sponsor_name":"Tribhuvan University Teaching Hospital, Institute Of Medicine.","has_results":false},{"nct_id":"NCT05677256","title":"A Study to Evaluate Pharyngeal Immunity to Poliovirus Type-2","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Fidec Corporation","has_results":false},{"nct_id":"NCT03286803","title":"Comparison of Immunity Following IPV Versus fIPV: a Community Based Randomized Controlled Trial in Pakistan","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Aga Khan University","has_results":false},{"nct_id":"NCT07457060","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":480,"lead_sponsor_name":"Sinovac Biotech Co., Ltd","has_results":false},{"nct_id":"NCT00352963","title":"Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":480,"lead_sponsor_name":"GlaxoSmithKline","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}